RedHill Biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
Latest News
-
February 15th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began -
February 13th, 2012
RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Prevention of Nausea and Vomiting) -
February 7th, 2012
RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) -
February 2nd, 2012
Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients) -
January 2nd, 2012
IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial
See More News